• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Autologous Stem Cell Transplant Can Improve Survival in MM Patients

Article

Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.

Survival in newly diagnosed multiple myeloma improved significantly in patients who underwent early autologous stem cell transplantation (ASCT), according to pooled data from two randomized trials.

The 4-year overall survival was 85% in patients who underwent stem cell transplantation as consolidation therapy versus 76% for those who had transplants after first relapse, reported Federica Cavallo, MD, PhD, of the University of Torino in Italy, and colleagues.

Median time to first progression (PFS1) was almost twice as long in patients who had early stem cell transplantation, and the time to second relapse also was significantly delayed by early transplantation, they said at the European Hematology Association meeting.

Read the original report here: http://bit.ly/V5ycMW

Source: Medpage Today

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.